Dr. Éric Poirier is a surgeon-oncologist at the CHU de Québec-Laval University. He is also a clinical researcher at the Research Center of the CHU de Québec-Laval University, and clinical professor at the Faculty of Medicine of Laval University. Dr. Poirier is part of the research group of the Centre des Maladies du Sein of CHU de Québec-Laval University.
Using structured breast cancer data
The research team of the Centre des Maladies du Sein has a comprehensive database of all cancers diagnosed since 1974; more than 12,000 patients are listed. A database of biopsy data from 1999 is also available; data on more than 34,000 biopsies are listed. These databases allow quality publications that modify the management and management of cancers and benign breast diseases.
Offer innovative treatments
The Centre des Maladies du Sein of CHU de Québec-Laval University research group is one of the largest in Canada, offering innovative treatments for breast cancer. More than 50 clinical trials are active at all times and are offered to patients who consult at the clinic or are referred by clinics/hospitals in the area. These clinical trials provide access to innovative experimental medications and develop the expertise of our world-renowned oncologists.
Support the quality of life
The Centre des Maladies du Sein of CHU de Québec-Laval University research group is a pioneer in quality of life studies in breast cancer, from total mastectomy to partial mastectomy, to the use of the cooling cap to counteract hair loss, promoting physical activity to improve survivorship, including optimal preservation of the axillary lymph nodes. The research group is at the forefront of studies promoting quality of life despite the adverse effects of the disease on an individual’s life.
1050, chemin Sainte-Foy
Centre des maladies du sein Deschênes-Fabia
Canada G1S 4L8
Data not available
Management of Oligometastatic Breast Cancer: An Expert Committee's OpinionJournal Article
Curr Oncol, 30 (2), 2023.
Do Preoperative Prophylactic Antibiotics Reduce Surgical Site Infection Following Wire-Localized Lumpectomy? A Single-Blind Randomized Clinical TrialJournal Article
Ann Surg Oncol, 29 (4), 2022.
Association of Breast Tumour Expression of Cannabinoid Receptors CBR1 and CBR2 with Prognostic Factors and Survival in Breast Cancer PatientsJournal Article
J Pers Med, 11 (9), 2021.
Impact of the introduction of formal D2 lymphadenectomy for gastric cancer in a Western settingJournal Article
Can J Surg, 64 (2), 2021.
In response to: Long-term overall survival of patients diagnosed with pure tubular carcinoma of the breast might be affected by increased co-morbiditiesJournal Article
J Surg Oncol, 117 (7), 2018.
Characteristics and long-term survival of patients diagnosed with pure tubular carcinoma of the breastJournal Article
J Surg Oncol, 117 (6), 2018.
How Wide Should Margins Be for Phyllodes Tumors of the Breast?Journal Article
Breast J, 23 (3), 2017.
Metastatic pattern of invasive lobular carcinoma of the breast-Emphasis on gastric metastasesJournal Article
J Surg Oncol, 115 (3), 2017.
Is clinical breast examination important for breast cancer detection?Journal Article
Curr Oncol, 23 (4), 2016.
Is there an Upgrading to Malignancy at Surgery of Mucocele-Like Lesions Diagnosed on Percutaneous Breast Biopsy?Journal Article
Breast J, 22 (2), 2016.
- NSABP Breast Cancer Treatment Protocols, from 1997-02-01 to 2025-12-25
Recently finished projects
- MA-12: Étude randomisée à double insu visant à comparer le tamoxifène avec un placebo chez les patientes atteintes d'un cancer du sein étendu aux ganglions lymphatiques et qui ont complété une chimiothérapie adjuvante ..., from 1997-04-01 to 2021-03-31